financetom
Business
financetom
/
Business
/
Together AI notches $3.3 billion valuation after General Catalyst-led fundraising
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Together AI notches $3.3 billion valuation after General Catalyst-led fundraising
Feb 20, 2025 9:39 AM

Feb 20 (Reuters) - Nvidia ( NVDA )-backed Together AI

said on Thursday it has raised $305 million in its latest

funding round, which more than doubled the

artificial-intelligence startup's valuation from last year.

The round, led by venture capital firm General Catalyst,

valued the San Francisco, California-based company at $3.3

billion.

Salesforce Ventures, chip giant Nvidia ( NVDA ) and Coatue also

participated in the fundraising, which was co-led by Prosperity7

- the venture capital fund of Aramco Ventures.

The new funding comes as Together AI looks to expand its

cloud platform, with plans for large-scale deployment of Nvidia

Blackwell graphics processing units.

Founded in 2022, Together AI's cloud platform allows

developers and researchers to train and deploy generative AI

models.

Last year, the company had raised $106 million in a

Salesforce Ventures-led funding round at $1.25 billion

valuation. It quickly gained popularity for offering access to

Nvidia's ( NVDA ) sought-after GPUs.

Together AI's platform supports more than 200 open-source

models, including Meta Platforms' Llama and those from China's

DeepSeek.

DeepSeek's launch of its latest low-cost AI models last

month has disrupted the industry and raised doubts over the

United States' lead in the race to dominate the technology.

"Recent developments in open-source AI illustrate the

importance of Together AI's work in making access to models like

these secure, accessible, and powerful for organizations here in

the U.S. and around the world," said Prosperity7 Ventures

Managing Director Abhishek Shukla.

Together AI increased its user base to more than 450,000 AI

developers last year, it said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Target Plunges 21% While Williams-Sonoma Soars 27% On Same Day
Target Plunges 21% While Williams-Sonoma Soars 27% On Same Day
Nov 20, 2024
Investors were treated to quite the pair trade on Wednesday when shares of big box retailer Target Corp ( TGT ) sunk while shares of home furnishing retailer Williams-Sonoma, Inc. ( WSM ) rocketed off earnings. The two stocks were the biggest movers of the day, according to Benzinga Pro. Price Action: Target’s stock closed the day at $121.72, down...
Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe
Nurix Therapeutics Gets Priority Medicines Label for NX-5948 in Europe
Nov 20, 2024
05:45 PM EST, 11/20/2024 (MT Newswires) -- Nurix Therapeutics ( NRIX ) said Wednesday it received PRIME designation from the European Medicines Agency for NX-5948 to treat adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The PRIME, or priority medicines, designation follows encouraging safety and efficacy data from an ongoing phase 1 trial, the company...
Update: Reddit Users Report Possible Outages, Tracking Website Says
Update: Reddit Users Report Possible Outages, Tracking Website Says
Nov 20, 2024
05:46 PM EST, 11/20/2024 (MT Newswires) -- (Adds company's response, other details throughout.) Reddit ( RDDT ) late Wednesday said it was returning to normal operations after a bug in a recent software update resulted in outages for some users of the social media company earlier this afternoon. Downdetector, which monitors outages and user problems on websites operated by companies...
Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug
Kura Oncology, Kyowa Kirin to Jointly Develop of Blood Cancer Drug
Nov 20, 2024
05:46 PM EST, 11/20/2024 (MT Newswires) -- Kura Oncology ( KURA ) and Kyowa Kirin said Wednesday that will develop and commercialize ziftomenib for the treatment of patients with blood cancer. Kura will receive $330 million in upfront payment and up to $420 million in near-term milestone payments, according to the companies. It will also be eligible for $741 million...
Copyright 2023-2026 - www.financetom.com All Rights Reserved